Insulet (PODD) EPS (Weighted Average and Diluted) Growth (3y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.66% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.81% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -1.10% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 62.43% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 10.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 61.98% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 27.51% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 6.01% |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn | 56.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.37% |
| Dec 31, 2025 | 78.84% |
| Sep 30, 2025 | 159.62% |
| Jun 30, 2025 | 38.21% |
| Mar 31, 2025 | 7.72% |
| Dec 31, 2024 | 48.67% |
| Sep 30, 2024 | 81.71% |
| Jun 30, 2024 | 108.01% |
| Dec 31, 2023 | 97.07% |
| Sep 30, 2023 | 63.28% |
| Jun 30, 2023 | 21.03% |
| Mar 31, 2023 | 137.13% |
| Dec 31, 2022 | 46.20% |
| Sep 30, 2022 | -115.44% |
| Jun 30, 2022 | -200.00% |
| Mar 31, 2022 | 78.78% |
| Dec 31, 2021 | 37.95% |
| Sep 30, 2021 | 81.71% |
| Jun 30, 2021 | -131.04% |
| Dec 31, 2020 | -29.40% |
| Sep 30, 2020 | 84.20% |
| Dec 31, 2019 | 412.62% |